EP 1051166 A1 20001115 - PHARMACEUTICAL USES OF OPTICALLY PURE (+) -BUPROPION
Title (en)
PHARMACEUTICAL USES OF OPTICALLY PURE (+) -BUPROPION
Title (de)
PHARMAZEUTISCHE ANWENDUNGEN VON OPTISCH REINEM (+)-BUPROPION
Title (fr)
UTILISATIONS PHARMACEUTIQUES DE (+)-BUPROPION OPTIQUEMENT PUR
Publication
Application
Priority
- US 9901952 W 19990128
- US 7295598 P 19980129
Abstract (en)
[origin: WO9938502A1] Methods and compositions are disclosed utilizing the optically pure (+)-isomer of bupropion, which is a potent drug for treating depression, Parkinson's disease, obesity, weight gain, bipolar, attention-deficit or conduct disorders, phychosexual dysfunction, bulima, eating disorders or specific food craving. The composition can be administered intravenously, transdermally (patch) or orally, possibly in a sustained release form.
IPC 1-7
IPC 8 full level
A61K 9/20 (2006.01); A61K 9/22 (2006.01); A61K 9/48 (2006.01); A61K 9/52 (2006.01); A61K 9/70 (2006.01); A61K 31/135 (2006.01); A61K 31/137 (2006.01); A61P 1/14 (2006.01); A61P 3/04 (2006.01); A61P 15/10 (2006.01); A61P 25/00 (2006.01); A61P 25/14 (2006.01); A61P 25/16 (2006.01)
CPC (source: EP)
A61K 31/135 (2013.01); A61K 31/137 (2013.01); A61P 1/14 (2017.12); A61P 3/04 (2017.12); A61P 15/10 (2017.12); A61P 25/00 (2017.12); A61P 25/14 (2017.12); A61P 25/16 (2017.12)
Citation (search report)
See references of WO 9938502A1
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
DOCDB simple family (publication)
WO 9938502 A1 19990805; AU 2483499 A 19990816; CA 2318960 A1 19990805; EP 1051166 A1 20001115; JP 2002501890 A 20020122
DOCDB simple family (application)
US 9901952 W 19990128; AU 2483499 A 19990128; CA 2318960 A 19990128; EP 99904433 A 19990128; JP 2000529235 A 19990128